Nxera Pharma Co., Ltd. (TYO:4565)
Japan flag Japan · Delayed Price · Currency is JPY
1,677.00
-68.00 (-3.90%)
Nov 18, 2026, 10:50 AM JST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

2027 could bring phase III data for direclidine and progress on cleminorexton, while the AbbVie deal and Japan portfolio support profitable growth. NEXAQ’s first AI-designed molecules are targeted for lab testing in Q1 2027.

Moderator

Okay, let's get started. Good evening, everyone. Thank you very much for joining Jefferies Global Healthcare Conference. My name is Miyabi Yamakita. I cover Japanese biotech companies at Jefferies in Tokyo. Today, we are joined by Nxera, represented by CEO Chris Cargill, CFO Hironoshin Nomura, and Chief Scientific Officer Patrik Foerch. Thank you very much for joining. Chris, I think you have a presentation, so over to you.

Chris Cargill
CEO, Nxera

Excellent. Okay, thank you, Miyabi. Thank you to Jefferies for hosting us again this year. I'll try and keep the presentation quite brief, hopefully under 10 minutes, and then Hiro and Patrik and I will take any questions that you may have. Okay, so five points to start. The first is that 2027 matters for two medicines that came out of our U.K. research labs. Our partner, Neurocrine, expects the first phase III data for a drug called direclidine that they're testing in schizophrenia. Lilly have a phase II/III study of an orexin two agonist, cleminorexton, in narcolepsy, which is also potentially due to complete next year. The second point, we're profitable. Revenue in the first nine months was up 27% to $177 million, $63 million of that was core operating profit. So very unique amongst biopharma tech bioscene.

I guess the third point is we've got 20 years of insights and data when it comes to our preferred target class, which is GPCRs. Nobody else has access to this data, and we're putting AI to work with it. I think fourth point is earlier this month, AbbVie licensed one of our novel first-in-class programs, an EP4 agonist, NXE744. We will hopefully receive $100 million upfront before the end of the year. The fifth point, eight molecules from our labs are in clinical trials with partners now, and our partnerships carry, give or take, $6 billion U.S. dollars in headline value plus royalties. So there's a lot going on at Nxera. I'll just click through these bits. Okay. So we run two businesses, and each one funds the other. So in Japan, we sell specialist medicines.

So on the left-hand side there, you can see we've got PIVLAZ, which prevents vasospasm after a brain bleed. It's the standard of care in Japan with a 74% market share. QUVIVIQ, we sell in Japan for insomnia. It's sold via our commercial partner, Shionogi, and its recently launched sales are growing rapidly. It grew 43% in the first nine months. AGAMREE for Duchenne muscular dystrophy is approved in the U.S., Europe, the U.K., and China, and we plan to file in Korea and Japan. We've already filed in Korea, actually. That's coming up. It could potentially launch next year. We're going to file in Japan in the second half of 2027. In October, we actually in-licensed a fourth product for our pipeline in Japan. This is lucerastat. So it's an oral treatment, potentially one of the first oral treatments for Fabry disease.

It's going to be entering phase III imminently. On the right-hand side, platform business in the U.K. Here, we build assets to partner. As you can see, we've been very successful at that. We discover medicines, and we license them, or we spin them. Partners pay us milestones as those programs advance, and royalties, hopefully someday, once those products are sold. The model that we run, those two businesses, is profitable. In February, we gave a guidance range. The top of that range assumed that we would be able to complete one substantive partnering deal this year. We did that with AbbVie. We delivered that a few weeks ago, and hopefully it will close before the end of the year. As a result, we've set guidance at the top of the range.

Revenues of JPY 48.8 billion, core operating profit for the year of JPY 22.8 billion, and operating profits of JPY 15.7 billion. That assumes that the AbbVie upfront is booked this quarter by the end of the year, and that does depend on antitrust clearance and on our auditors. I'll touch on direclidine. I mentioned it earlier. It's an M4 agonist that we discovered and licensed to our partner, Neurocrine Biosciences. It's in phase III for schizophrenia. Neurocrine expects the first phase III data in the second half of 2027, with more data in 2028. Neurocrine's also testing direclidine in bipolar mania and three more muscarinic molecules from our labs in schizophrenia and Alzheimer's disease.

This agreement with partner Neurocrine Biosciences is worth up to $2.6 billion in milestones, plus there'll be royalties from high single digits up to the mid-teens, should any of the products ultimately become approved. AbbVie, the most recent transaction that I mentioned that we entered into, this is NXE744. It's a pill for inflammatory bowel disease. It's designed to work in the gut and keep exposure in the rest of the body low. It acts on EP4, a receptor that helps protect and repair the gut lining. Most current treatments work on the immune system, so this is a slightly different approach. In phase I, the drug stayed in the gut and engaged its target well. AbbVie, as I mentioned, they've licensed exclusive worldwide rights in IBD. Hopefully we receive the $100 million upfront before the end of the year.

There's $1.37 billion in milestones, with some of those milestones potentially near term. There's obviously tiered royalty should the product ever become commercially available. We're really happy with the partnership. AbbVie, clearly a leader in IBD, and they were already a partner of ours on the neuroscience front as well. Taken together, there's eight partnered molecules in the clinic. Two of them are in late-stage studies. Lilly acquired Centessa earlier this year in June, and Lilly are now running the orexin programs, led by cleminorexton. We earn milestones and royalties across all those three molecules as well. All told this year, partners paid us $85 million in the first nine months, and the platform business, which we run from the U.K., made $17 million of core operating profit.

Some people ask us, "Why do partners keep coming to us?" When it comes to GPCRs, our data and our know-how is unsurpassed. GPCRs are the receptors behind about a third of all approved medicines worldwide. Over the last 20 years, we've determined 520 GPCR structures. We've built 30,000 mutation points around how to stabilize those to enable medicinal chemistry. Lots of people can rent computing power, they can buy AI models, but it's the data and the know-how that makes the ultimate difference, and we're getting faster and faster. Finding the first active molecules for a new target now takes us about half the time it used to in 2025. This new evolution of our platform that we've been building is called NEXAQ. The A stands for AI and the Q stands for QM.

NEXAQ is how we apply AI and quantum mechanics to that data. AI suggests and ranks the molecules, physics-based and quantum methods check that shortlist, and our chemists remain in the loop to make decisions around what we should make, and every result goes back into our data lake in our system to help make our drug discovery timelines a lot faster. It's up and running on all of our historical data now. We're going to test the first AI-designed molecules in the lab in the first half of next year, and we aim for the first lead series hopefully in the second half of next year. On the emerging pipeline, there's really two parts. There's clinical programs across neurology, inflammation, and cancer, and then there's a next wave of oral medicines that we are developing for metabolic and rare endocrine diseases.

We have two clinical programs that are still ours, in-house, and they are to be partnered. NXE149 is a novel first-in-class GPR52 agonist for schizophrenia. The phase I is complete, ready for phase II, and discussions are continuing, and we intend to partner it next year in 2027. NXE732 is an EP4 antagonist for solid tumors. Cancer Research UK is our partner. They fund and operationalize the phase II-A trial. In phase I, when it was given with an immunotherapy, it produced two partial responses. We'll report the interim data as soon as it's available, hopefully later this year or early next year. Again, that is a program that we are looking to partner. This is the next wave of the in-house pipeline that we're working on. The next wave is predominantly once-daily pills aimed at hormone receptors that are already proven.

GLP-1, GIP, amylin for obesity, plus programs for thyroid eye disease and hypoparathyroidism. We think the markets are large, and this slide shows some of the Evaluate estimates for what those markets could look like in the 2030s and beyond. These programs are very early, it's why they're part of the next wave of our pipeline, but we will take them to development candidate or phase I stage before we decide what our strategy is. Our predominant focus is usually on building these programs and partnering them with large multinational pharma or biotech companies once we've got to the end of phase I. Lastly, I'll just end on the path to 2030 for our company. Our 2030 targets haven't changed. Revenues, we want sustainable, stable revenues of JPY 50 billion or more, which is up from JPY 28.8 billion in 2024.

We want to target operating margins, operating profit margins of 30% or above by 2030, and 40% or above by the mid-2030s, so 2035. The revenue growth comes from four places. There is the products that we already sell today in our commercial business in Japan, the expected launch of AGAMREE for DMD in Japan in 2028, the new rare disease products that we will license and have recently licensed, such as lucerastat, plus all of the milestone income and hopefully royalties that come from the partnered programs that I have discussed today. The operating margin largely comes from having a very lean specialist sales force in Japan. We have new products that go into the same hospitals and call points. We have royalty income, which drops straight through to profit, and we have a discovery engine that is increasingly costing less per development candidate.

That is kind of the secret sauce of our company. We are very profitable in Japan, we are discovering new medicines in the U.K., and we seek to partner those medicines with the world. That was everything I wanted to run through. Yamakita-san, we are all ready for Q&A.

Moderator

Yeah, thank you very much, Chris. I have a couple of questions. I would like to start with the biggest news recently, the biggest news, EP4 agonist license out. Could you talk a little bit more about the positioning? I understand the mechanism of action is different from existing one, but is your compound going to be used with monotherapy or combination, and how is your phase II trial design? Is it monotherapy or combination therapy?

Chris Cargill
CEO, Nxera

Cool

Moderator

potentially?

Chris Cargill
CEO, Nxera

I will ask Patrik to respond, but just before he does, I just want to be very clear. AbbVie have licensed a molecule, it is now their molecule, so we have got to be very careful around what we say. Anything that we say is really just, it reflects our planning when the molecule was in our hands and how we might think we would take it forward. Anything we say is not attributed to AbbVie, if that is okay. But Patrik, did you want to just touch on that a little bit?

Patrik Foerch
Chief Scientific Officer, Nxera

Yeah. Maybe just mechanistically, obviously, EP4 is helping barrier repair the gut, which is obviously additive to the anti-inflammatory approach. On the other hand, you've also got a slight anti-inflammatory modality as well. Based on these two mechanisms, you could theoretically see a path forward as a monotherapy, but on the other hand, you could also see this being used as an add-on therapy. I would say when you look at our phase I data, it's very clear that we have a very attractive profile. It's gut-restricted. We have data that we can engage the target from some permeability studies that we've done, and we have clear sign of biomarkers that we can engage the targets. I think that leaves quite a few options open for AbbVie to take it forward, but as Chris said, we can't comment on what really AbbVie's plans are.

Moderator

Okay, thank you very much. Let's move on to your in-house compound, EP4 antagonist. You're currently doing phase II trial with a combination therapy. Do you have any idea of further combination beyond the current combination?

Chris Cargill
CEO, Nxera

That is a good question. We're certainly thinking about it. You're talking about the EP4 antagonist, right, Miyabi?

Moderator

Yes.

Chris Cargill
CEO, Nxera

Yeah, yeah.

Moderator

You got it.

Chris Cargill
CEO, Nxera

Yes, the EP4 antagonist, there is another Japanese company out there that is forging ahead with a path in gastric and GEJ cancer. That is looking quite promising, and clearly we could follow in that path as well. Given the MOA, we are thinking quite aggressively around which other emerging immunotherapies or other mechanisms it could be positioned with, but we certainly don't have anything locked down at this stage. There are a number of companies, including many Japanese companies actually, that are showing a very strong interest in gastric cancers, and that's largely because that part of the world suffers disproportionately from gastric cancers relative to the rest of the world. We are thinking proactively of ways where this program could be synergistic with the pipeline products that others are holding right now. Patrik, did you want to add anything to that?

Patrik Foerch
Chief Scientific Officer, Nxera

Maybe just around another EP4 molecule to the gastric cancer, that is now moving forward as first-line treatment, which obviously moves this early up the cascade, which would be potentially very attractive positioning relative to what people have usually attributed as potential indications for EP4 antagonism.

Moderator

Got it. Thank you very much. I'd like to also ask about your capital allocation. I think your commercial business generates decent size of cash flow, so what are you going to use this cash for? Debt repayment or further in licensing new assets to Japan, APAC?

Chris Cargill
CEO, Nxera

Sure. I will let our CFO, Hiro, comment on that, and I can give some additional points if you want.

Hironoshin Nomura
CFO, Nxera

Sure, yeah. That is very happy. We are very happy after three years of acquisition with Idorsia. Now our commercial business becoming a very strong cash cow business for us. Of course, there is some, how can I say, repayment for our debt, which we use for the acquisition is coming from this commercial cash cow. But still, we have enough additional cash we can use. So it actually depends which is the best for use of this money. Sometimes we are very seriously thinking about the corp strategic action, including the in-licensing matters, which can create more stronger business or commercial business in near future. Of course, sometimes the U.K. R&D business, even we are make this business more efficient and efficient. However, of course, sometimes we are thinking it is a good opportunity to invest. Of course, we can do that.

But such kind of balance we are always thinking, but not clearly can say now, but we are always thinking about a lot of things.

Chris Cargill
CEO, Nxera

Yeah. We have a very successful track record when it comes to transaction activity, whether that is out-licensing or spinning molecules from our U.K. business, in-licensing molecules for our Japanese business, or doing M&A transactions. It is really helpful that that business in Japan now does have such strong and growing cash flows, because it means we have been able to rapidly build a pipeline in Japan. Those four products, two of them are launched, two of them I have very high confidence will launch in the next two to five years. That is a business we want to add to, so we are going to add more products. So those cash flows will be used for more in-licensing. But as Hiro said, we have other responsibilities at times, such as paying down our corporate debt facilities, and it really just depends.

We always try and remain very flexible so that we can pounce and transact quickly, and that's how we've been so successful, I think, in being able to build such a quality pipeline in such a short period of time.

Moderator

Okay, thank you very much. In terms of your AI-created technology, when can we expect to see the outcome from the technology?

Chris Cargill
CEO, Nxera

Yeah, very good question. The way I think about this, we're running Our core business in Cambridge is the benchmark, so it's already incredibly efficient and incredibly productive, and it kind of sets the pace for what we are trying to beat. Of course, all of that data, the historic data we have and the data that we continue to generate from that business, is what is fueling AI. We hope that the AI can materially compress the front end of drug discovery. So we're really focusing on speed to development candidate and really crushing the timelines it takes to move through sort of hit ID, hit expansion, get to an optimized lead. That's where we think it can have the most impact for us.

As I mentioned earlier in the presentation, the first purely AI-generated molecules will be tested in the lab in the first quarter of next year, and that will be the first sign that we get to see whether or not this is actually really something we can throw a bit more capital behind. Then, the aim, the long-term aim, at the moment it remains aspirational, but in the mid-term, I believe it's achievable, is to be able to go from starting on a target to delivering a development candidate within 18 months, which then puts you in the clinic in two to 2.5 years. That is the dream scenario for us, and if we can use AI and QM to support our business in the U.K. to do some of that work faster, then everybody's going to win. Patients, shareholders, et cetera.

Moderator

Okay, thank you very much. We have about five minutes left, so I would like to open the floor to questions. Does anyone have any questions? Then I have another question about your cost base. How do you expect your cost base next year?

Chris Cargill
CEO, Nxera

Nomura-san?

Hironoshin Nomura
CFO, Nxera

Yeah, sure. Thank you for asking me a question. Actually, our full-year result is scheduled next February, so at that point, we can disclose a bit more. As you see, our current P&L, which we announced the third quarter results three weeks ago, we succeeded to reduce our COGS 30%, SG&A 10%, and R&D 20% so far compared with the previous year's third quarter. Of course, I cannot say any solid, but in our practice and in our culture, we are always searching, always searching very hard to make our business more efficient, especially nowadays, AI and the tools very helpful to make it. We cannot guarantee it. However, as a business usual, we would like to make it more efficient.

Chris Cargill
CEO, Nxera

Yeah. I think the best way to think about our cost structure is that we are always trying to drive down COGS to increase margin. We have a team in Switzerland that is resolutely focused on that initiative. From an R&D perspective, unlike a traditional U.K. or U.S. biotech, we do not accelerate or scale up the spend of R&D. We try and hold R&D spend flat and make the operations more efficient. Basically, putting more programs and products through the pipeline, but spending the same amount of money that we did the year before. If we have opportunities to move programs into the clinic, then we dynamically readjust the pipeline and the portfolio so that we can back the best bets and hold or even potentially cull those programs which we do not think are good from a return on investment perspective.

G&A, we generally are going to hold flat going forward, and sales and marketing only ever needs to expand as and when we add new products to the portfolio. But for now, it is very well managed. Unlike other companies in Japan, we are not a company that spends maximally on promotional activity right up until the LOE of a product. We take it to peak sales, and then we look for cost out so that we can make the products as profitable as possible. We have a very different approach, I guess, to a traditional scaling biotech. We are very conscious of our cost structure, and we try to keep it as flat as possible so that when new products come in or milestones come in, we get the maximal benefit from the operating leverage.

Moderator

Interesting. Thank you very much. Any questions from the floor? May I ask about vamorolone? I think there are a decent size of market in Japan for DMD, but could you explain how your vamorolone differ from the traditional steroid in DMD?

Chris Cargill
CEO, Nxera

Yep, sure. Thank you. Agamree or vamorolone, really important product for us. It's going to be the next one that we launch. We had some amazing news last week that in Korea, it had been accepted into an accelerated review program, one of five products that were shortlisted from a group of about 15 or 20 programs. It'll likely launch in Korea ahead of Japan, actually. Vamorolone is essentially, it's a safer steroid. Long-term use of traditional steroids in patients with DMD can stunt their growth and weaken their bones. Where vamorolone is different is it keeps the anti-inflammatory effects, but it has less of a side effect profile. It's a much safer steroid. It's a baseline therapy for patients with DMD. They can stay on it for longer, potentially get onto the drug earlier, which is really beneficial for patients.

For us, it's a perfect example of a product that fits really well with what we're trying to do in Japan, which is bring medicines to patients that haven't previously had access to those medicines. You've got to remember, vamorolone is approved in the U.S., the U.K., Europe, China, but it was not developed in Japan. We had a great discussion with the PMDA, and they have waved us through. We do not have to do local bridging studies, so we're just absolutely foot on the gas trying to make this medicine available for patients in Japan as fast as possible, and we're really excited to launch it in 2028.

Moderator

Thank you very much. We are running out of time, so let's conclude this session here. Thank you very much for joining, everyone.

Chris Cargill
CEO, Nxera

Thank you.